azacitidine has been researched along with edetic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aird, RE; Chen, H; Cummings, J; Jodrell, DI; Morris, RE; Muir, M; Ritchie, AA; Sadler, PJ | 1 |
1 review(s) available for azacitidine and edetic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for azacitidine and edetic acid
| Article | Year |
|---|---|
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Calcium Channel Blockers; Carboplatin; Cisplatin; Decitabine; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Edetic Acid; Female; Humans; Ligands; Mice; Mice, Nude; Neoplasm Proteins; Organometallic Compounds; Ovarian Neoplasms; Ruthenium Compounds; Structure-Activity Relationship; Verapamil; Xenograft Model Antitumor Assays | 2002 |